Literature DB >> 12704648

What it takes to become an effector T cell: the process, the cells involved, and the mechanisms.

M A Santana1, Y Rosenstein.   

Abstract

When activated, CD4(+) T cells differentiate into two major sub-populations differing in their profiles of secreted cytokines. Type One, or TH1, cells secrete IL-2, IFNgamma, and TNFbeta and mediate a cellular immune response. Type Two, or TH2, cells secrete IL-4, IL-5, IL-6, IL-10, and IL-13 and potentiate a humoral response. The nature of any specific immune response depends on the interaction of antigen-presenting cells and T cells. The role of antigen-presenting cells is to respond to the nature of the immune challenge and signal differentiation of CD4(+) T cells. A number of factors are involved in the effector phenotype of T cells-nature and affinity of antigen, co-receptors signals, and cytokine environment. T-cell differentiation is a complex process comprising four defined developmental stages: activation of particular cytokine genes, commitment of the cells, silencing of the opposing cytokine genes, and stabilization of the phenotype. In each of these stages, the cells respond to the products of many signaling cascades from many membrane-bound receptors. The stages in development are mediated by different molecular mechanisms, involving control of gene expression and chromatin remodeling. This review centers on the factors, cellular interactions, and molecular mechanisms involved in the maturation of naïve CD4(+) T lymphocytes into fully effector cells. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704648     DOI: 10.1002/jcp.10258

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  22 in total

Review 1.  Molecular dialogs between the ischemic brain and the peripheral immune system: dualistic roles in injury and repair.

Authors:  Chengrui An; Yejie Shi; Peiying Li; Xiaoming Hu; Yu Gan; Ruth A Stetler; Rehana K Leak; Yanqin Gao; Bao-Liang Sun; Ping Zheng; Jun Chen
Journal:  Prog Neurobiol       Date:  2013-12-26       Impact factor: 11.685

Review 2.  Immune modulation to improve tissue engineering outcomes for cartilage repair in the osteoarthritic joint.

Authors:  Niamh Fahy; Eric Farrell; Thomas Ritter; Aideen E Ryan; J Mary Murphy
Journal:  Tissue Eng Part B Rev       Date:  2014-08-04       Impact factor: 6.389

Review 3.  Biocompatibility of implants: lymphocyte/macrophage interactions.

Authors:  James M Anderson; Amy K McNally
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

4.  Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma.

Authors:  Johannes E A Wolff; Sabine Wagner; Christiane Reinert; Astrid Gnekow; R-D Kortmann; Joachim Kühl; Stefaan W Van Gool
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

5.  Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo.

Authors:  Sewon Kang; Soyun Cho; Jin Ho Chung; Craig Hammerberg; Gary J Fisher; John J Voorhees
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

Review 6.  Importance of T lymphocytes in brain injury, immunodeficiency, and recovery after cerebral ischemia.

Authors:  Vanessa H Brait; Thiruma V Arumugam; Grant R Drummond; Christopher G Sobey
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-01       Impact factor: 6.200

7.  Foreign body-type multinucleated giant cells induced by interleukin-4 express select lymphocyte co-stimulatory molecules and are phenotypically distinct from osteoclasts and dendritic cells.

Authors:  Amy K McNally; James M Anderson
Journal:  Exp Mol Pathol       Date:  2011-07-23       Impact factor: 3.362

8.  Lymphocyte adhesion and interactions with biomaterial adherent macrophages and foreign body giant cells.

Authors:  David T Chang; Erica Colton; Takehisa Matsuda; James M Anderson
Journal:  J Biomed Mater Res A       Date:  2009-12-15       Impact factor: 4.396

Review 9.  Vaccine adjuvants: current challenges and future approaches.

Authors:  Jennifer H Wilson-Welder; Maria P Torres; Matt J Kipper; Surya K Mallapragada; Michael J Wannemuehler; Balaji Narasimhan
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

10.  Paracrine and juxtacrine lymphocyte enhancement of adherent macrophage and foreign body giant cell activation.

Authors:  David T Chang; Erica Colton; James M Anderson
Journal:  J Biomed Mater Res A       Date:  2009-05       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.